The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

A Phase I Study of the CSF1R Kinase Inhibitor PLX3397 for PVNS

William D. Tap, MD
Published Online: 9:52 PM, Sun June 1, 2014
William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor PLX3397 for the treatment of pigmented villonodular synovitis (PVNS).

<<< Back to the ASCO 2014 conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.